Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

a series of patent infringement lawsuits were filed against Moderna and collaborators Pfizer+BioNTech seeking damages based on their respective sales of the Spikevax® and Comirnaty® COVID-19 ...

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

Pfizer stock has delivered its long-term shareholders a dividend that has grown for 16 consecutive years. The pace of those ...

As we head into winter illness season, the SMC asked experts for the latest on ou. An updated vaccine targeting new COVID ...

The drug will be made available to people with private health insurance from the start of next year, said Pfizer. Comirnaty sales, meanwhile, are expected to be around $2 billion lower than ...